Cumberland Pharmaceuticals (CPIX) Receivables (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of Receivables data on file, last reported at $14.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 35.98% year-over-year to $14.3 million; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (up 35.98% YoY), and the FY2025 full-year result was $16.9 million, up 44.81% from the prior year.
• Receivables declined to $14.3 million in Q1 2026, from $16.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $16.9 million in Q4 2025 to a low of $9.8 million in Q4 2023.
• A 5-year average of $12.5 million and a median of $12.2 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 91.41% in 2022 and slipped 26.72% in 2024, its largest moves.
• Tracing CPIX's Receivables over 5 years: stood at $13.2 million in 2022, then slipped by 25.87% to $9.8 million in 2023, then climbed by 19.91% to $11.7 million in 2024, then surged by 44.81% to $16.9 million in 2025, then dropped by 15.83% to $14.3 million in 2026.
• Business Quant data shows CPIX's Receivables at $14.3 million in Q1 2026, $16.9 million in Q4 2025, and $10.4 million in Q3 2025.